open access

Vol 73, No 2 (2022)
Clinical vignette
Submitted: 2021-11-28
Accepted: 2021-12-06
Published online: 2022-03-25
Get Citation

Therapeutic difficulties in an aggressive ACTH-secreting pituitary adenoma

Wanda Foltyn1
·
Pubmed: 35381097
·
Endokrynol Pol 2022;73(2):375-376.
Affiliations
  1. Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland

open access

Vol 73, No 2 (2022)
Clinical Vignette
Submitted: 2021-11-28
Accepted: 2021-12-06
Published online: 2022-03-25

Abstract

Not required for Clinical Vignette.

Abstract

Not required for Clinical Vignette.

Get Citation

Keywords

aggressive ACTH-secreting pituitary tumor; treatment; temozolomide

Supp./Additional Files (1)
Supplementary File
Download
213KB
About this article
Title

Therapeutic difficulties in an aggressive ACTH-secreting pituitary adenoma

Journal

Endokrynologia Polska

Issue

Vol 73, No 2 (2022)

Article type

Clinical vignette

Pages

375-376

Published online

2022-03-25

Page views

4983

Article views/downloads

568

DOI

10.5603/EP.a2022.0015

Pubmed

35381097

Bibliographic record

Endokrynol Pol 2022;73(2):375-376.

Keywords

aggressive ACTH-secreting pituitary tumor
treatment
temozolomide

Authors

Wanda Foltyn

References (4)
  1. Fountas A, Lavrentaki A, Subramanian A, et al. Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2018 [Epub ahead of print].
  2. Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018; 178(1): G1–G24.
  3. McCormack A, Dekkers OM, Petersenn S, et al. ESE survey collaborators. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018; 178(3): 265–276.
  4. Elbelt U, Schlaffer SM, Buchfelder M, et al. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. J Clin Endocrinol Metab. 2020; 105(3).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl